NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus

RecruitingN/A

Sponsor: AstraZeneca

Conditions: Chronic Lymphocytic Leukemia

Countries: Belarus

to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥18 years.
* Confirmed diagnosis of CLL.
* Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation.
* Treatment-naïve or R/R CLL.
* Ability and willingness to provide informed consent for study participation.

Exclusion Criteria:

* Patients not satisfying any of the inclusion criteria.
* Prior treatment with any BTK inhibitor.
* Participation in other ongoing clinical trials.
* Pregnant or breastfeeding females

Locations (3)

Grodno, Belarus
Homyel, Belarus
Minsk, Belarus